Interference of PTK6/GAB1 signaling inhibits cell proliferation, invasion, and migration of cervical cancer cells

Li,Juan; Yang,Nan; Tian,Xiaolei; Ouyang,Linglong; Jiang,Man; Zhang,Shufang

doi:10.3892/mmr.2022.12800

Interference of PTK6/GAB1 signaling inhibits cell proliferation, invasion, and migration of cervical cancer cells

Authors:
- Juan Li
- Nan Yang
- Xiaolei Tian
- Linglong Ouyang
- Man Jiang
- Shufang Zhang
View Affiliations

Affiliations: Department of Gynecology, Southern University of Science and Technology Hospital, Shenzhen, Guangdong 518055, P.R. China
Published online on: July 26, 2022 https://doi.org/10.3892/mmr.2022.12800
Article Number: 284
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein tyrosine kinase 6 (PTK6) has shown important cancer‑promoting effects in a variety of cancer types. Nonetheless, its vital role in cervical cancer has not been completely elucidated. The present study sought to address whether PTK6 is involved in the malignant progression of cervical cancer via its interaction with GRB2‑associated binding 1 (GAB1). Western blotting was used to examine PTK6 and GAB1 expression levels. Cell Counting Kit‑8, Transwell, wound healing, and terminal deoxynucleotidyl‑transferase‑mediated dUTP nick end labeling assays were performed to estimate the corresponding proliferative, migratory, invasive, and apoptotic abilities of the cells. Co‑immunoprecipitation (Co‑IP) assays confirmed binding of PTK6 to GAB1. The results revealed that the expression levels of PTK6 and GAB1 were markedly increased in cervical cancer cell lines compared with those noted in normal cervical epithelial cells. The cell proliferative, invasive, and migratory activities of cervical cancer cells were reduced in the absence of PTK6 expression, whereas the induction of apoptosis was aggravated under these conditions. The results of the Co‑IP assay indicated that PTK6 expression was positively associated with GAB1. In addition, the suppressive effect of PTK6 silencing on the malignant phenotypes of cervical cancer cells was reversed following overexpression of GAB1. In summary, the present study indicated that knockdown of PTK6 expression protected against the malignant progression of cervical cancer, while overexpression of GAB1 counteracted the inhibitory effects of PTK6 knockdown on cervical cancer cells.

View Figures

View References

1	Chen R, Sheng C, Ma R, Zhang L, Yang L and Chen Y: PLAC1 is an independent predictor of poor survival, and promotes cell proliferation and invasion in cervical cancer. Mol Med Rep. 24:8002021. View Article : Google Scholar : PubMed/NCBI
2	Auguste P: Cervical cancer screening: Updated guidelines from the American cancer society. Am Fam Physician. 104:314–315. 2021.PubMed/NCBI
3	Olusola P, Banerjee HN, Philley JV and Dasgupta S: Human papilloma virus-associated cervical cancer and health disparities. Cells. 8:6222019. View Article : Google Scholar : PubMed/NCBI
4	Hu Z and Ma D: The precision prevention and therapy of HPV-related cervical cancer: New concepts and clinical implications. Cancer Med. 7:5217–5236. 2018. View Article : Google Scholar : PubMed/NCBI
5	Wang XJ, Xiong Y, Ma ZB, Xia JC and Li YF: The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer. Chin J Cancer. 35:542016. View Article : Google Scholar : PubMed/NCBI
6	Shin WS, Shim HJ, Lee YH, Pyo M, Park JS, Ahn SY and Lee ST: PTK6 localized at the plasma membrane promotes cell proliferation and migration through phosphorylation of Eps8. J Cell Biochem. 118:2887–2895. 2017. View Article : Google Scholar : PubMed/NCBI
7	Zhao C, Chen Y, Zhang W, Zhang J, Xu Y, Li W, Chen S and Deng A: Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance. Onco Targets Ther. 6:183–188. 2013.PubMed/NCBI
8	Ito K, Park SH, Katsyv I, Zhang W, De Angelis C, Schiff R and Irie HY: PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells. NPJ Breast Cancer. 3:452017. View Article : Google Scholar : PubMed/NCBI
9	Fan G, Lin G, Lucito R and Tonks NK: Protein-tyrosine phosphatase 1B antagonized signaling by insulin-like growth factor-1 receptor and kinase BRK/PTK6 in ovarian cancer cells. J Biol Chem. 288:24923–24934. 2013. View Article : Google Scholar : PubMed/NCBI
10	Ito K, Park SH, Nayak A, Byerly JH and Irie HY: PTK6 inhibition suppresses metastases of triple-negative breast cancer via SNAIL-dependent E-cadherin regulation. Cancer Res. 76:4406–4417. 2016. View Article : Google Scholar : PubMed/NCBI
11	Ono H, Basson MD and Ito H: PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling. PLoS One. 9:e960602014. View Article : Google Scholar : PubMed/NCBI
12	Chen X, Song B, Lin Y, Cao L, Feng S, Zhang L and Wang F: PTK6 promotes hepatocellular carcinoma cell proliferation and invasion. Am J Transl Res. 8:4354–4361. 2016.PubMed/NCBI
13	Bongartz H, Gille K, Hessenkemper W, Mandel K, Lewitzky M, Feller SM and Schaper F: The multi-site docking protein Grb2-associated binder 1 (Gab1) enhances interleukin-6-induced MAPK-pathway activation in an SHP2-, Grb2-, and time-dependent manner. Cell Commun Signal. 17:1352019. View Article : Google Scholar : PubMed/NCBI
14	Simister PC and Feller SM: Order and disorder in large multi-site docking proteins of the Gab family-implications for signalling complex formation and inhibitor design strategies. Mol Biosyst. 8:33–46. 2012. View Article : Google Scholar : PubMed/NCBI
15	Vaughan TY, Verma S and Bunting KD: Grb2-associated binding (Gab) proteins in hematopoietic and immune cell biology. Am J Blood Res. 1:130–134. 2011.PubMed/NCBI
16	Shi XY, Wang H, Wang W and Gu YH: MiR-98-5p regulates proliferation and metastasis of MCF-7 breast cancer cells by targeting Gab2. Eur Rev Med Pharmacol Sci. 24:109142020.PubMed/NCBI
17	Tian J, Zhang H, Mu L, Wang M, Li X, Zhang X, Xie E, Ma M, Wu D and Du Y: The miR-218/GAB2 axis regulates proliferation, invasion and EMT via the PI3K/AKT/GSK-3β pathway in prostate cancer. Exp Cell Res. 394:1121282020. View Article : Google Scholar : PubMed/NCBI
18	Fang Z, Li T, Chen W, Wu D, Qin Y, Liu M, Wu G, He L, Li H and Gu H: Gab2 promotes cancer stem cell like properties and metastatic growth of ovarian cancer via downregulation of miR-200c. Exp Cell Res. 382:1114622019. View Article : Google Scholar : PubMed/NCBI
19	Campos-Viguri GE, Peralta-Zaragoza O, Jimenez-Wences H, Longinos-González AE, Castañón-Sánchez CA, Ramírez-Carrillo M, Camarillo CL, Castañeda-Saucedo E, Jiménez-López MA, Martínez-Carrillo DN and Fernández-Tilapa G: MiR-23b-3p reduces the proliferation, migration and invasion of cervical cancer cell lines via the reduction of c-Met expression. Sci Rep. 10:32562020. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Sahu R and Pattanayak SP: Strategic developments & future perspective on gene therapy for breast cancer: Role of mTOR and Brk/PTK6 as molecular targets. Curr Gene Ther. 20:237–258. 2020. View Article : Google Scholar : PubMed/NCBI
22	Li T, Wan Y, Su Z, Li J, Han M and Zhou C: SRF potentiates colon cancer metastasis and progression in a microRNA-214/PTK6-dependent manner. Cancer Manag Res. 12:6477–6491. 2020. View Article : Google Scholar : PubMed/NCBI
23	Xu XL, Ye YL, Wu ZM, He QM, Tan L, Xiao KH, Wu RY, Yu Y, Mai J, Li ZL, et al: Overexpression of PTK6 predicts poor prognosis in bladder cancer patients. J Cancer. 8:3464–3473. 2017. View Article : Google Scholar : PubMed/NCBI
24	Harvey AJ and Crompton MR: The Brk protein tyrosine kinase as a therapeutic target in cancer: Opportunities and challenges. Anticancer Drugs. 15:107–111. 2004. View Article : Google Scholar : PubMed/NCBI
25	Zheng Y and Tyner AL: Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer. Eur J Clin Invest. 43:397–404. 2013. View Article : Google Scholar : PubMed/NCBI
26	Dwyer AR, Kerkvliet CP, Krutilina RI, Playa HC, Parke DN, Thomas WA, Smeester BA, Moriarity BS, Seagroves TN and Lange CA: Breast tumor kinase (Brk/PTK6) mediates advanced cancer phenotypes via SH2-domain dependent activation of RhoA and Aryl hydrocarbon receptor (AhR) signaling. Mol Cancer Res. 19:329–345. 2021. View Article : Google Scholar : PubMed/NCBI
27	Ostrander JH, Daniel AR, Lofgren K, Kleer CG and Lange CA: Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res. 67:4199–4209. 2007. View Article : Google Scholar : PubMed/NCBI
28	Fan Y, Yang F, Cao X, Chen C, Zhang X, Zhang X, Lin W, Wang X and Liang C: Gab1 regulates SDF-1-induced progression via inhibition of apoptosis pathway induced by PI3K/AKT/Bcl-2/BAX pathway in human chondrosarcoma. Tumour Biol. 37:1141–1149. 2016. View Article : Google Scholar : PubMed/NCBI
29	Lang YD, Chen HY, Ho CM, Shih JH, Hsu EC, Shen R, Lee YC, Chen JW, Wu CY, Yeh HW, et al: PSPC1-interchanged interactions with PTK6 and β-catenin synergize oncogenic subcellular translocations and tumor progression. Nat Commun. 10:57162019. View Article : Google Scholar : PubMed/NCBI
30	Zheng Y, Wang Z, Bie W, Brauer PM, Perez White BE, Li J, Nogueira V, Raychaudhuri P, Hay N, Tonetti DA, et al: PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer. Cancer Res. 73:5426–5437. 2013. View Article : Google Scholar : PubMed/NCBI